Oncology
Genentech Inc. funds a broad oncology portfolio spanning advanced melanoma, non-small cell lung cancer, metastatic breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and advanced prostate cancer. Its studies also include HER2-expressing cancers, KRAS G12C-mutated solid tumors, and other locally advanced or metastatic solid tumors.
- Advanced melanoma and NRAS-mutant melanoma
- Breast cancer with ER-positive, HER2-negative disease
- KRAS-mutant solid tumors and metastatic gastrointestinal cancers
- B-cell malignancies and multiple myeloma
Research activity also extends to relapsed or refractory multiple myeloma, B-cell malignancies, and other hematologic cancers, alongside solid-tumor programs that target difficult-to-treat metastatic disease.
Respiratory and Fibrotic Disease
The sponsor supports research in chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and systemic sclerosis-associated interstitial lung disease. These programs reflect interest in chronic inflammatory and fibrotic conditions affecting lung function and respiratory health.
- Chronic obstructive pulmonary disease (COPD)
- Idiopathic pulmonary fibrosis
- Systemic sclerosis-associated interstitial lung disease
Additional work includes systemic sclerosis studies with pulmonary involvement, linking connective tissue disease research with progressive lung impairment.
Immunology and Inflammatory Disease
Genentech’s clinical research includes ulcerative colitis, systemic lupus erythematosus, and systemic sclerosis, with attention to both organ-specific and systemic autoimmune disorders. The portfolio also includes conditions with inflammatory and immune-mediated pathology such as lupus nephritis.
- Moderately to severely active ulcerative colitis
- Systemic lupus erythematosus with or without lupus nephritis
- Systemic sclerosis
These studies address immune dysregulation across gastrointestinal, renal, and connective tissue manifestations.
Rare and Genetic Disorders
The sponsor funds research in late-onset Pompe disease, a glycogen storage disorder with neuromuscular and metabolic consequences. This area adds a rare-disease dimension to its broader therapeutic portfolio.
- Pompe disease
- Glycogen storage disease type II
These programs focus on inherited disease biology and long-term functional impairment.
Cardiometabolic and Perioperative Conditions
Genentech also supports studies in acute kidney injury associated with cardiac surgery and in overweight or obesity in otherwise healthy participants. This expands its research landscape into perioperative renal risk and metabolic health.
- Cardiac surgery-associated acute kidney injury
- Overweight and obesity
These areas complement its disease-focused programs by addressing complications linked to surgery and body weight.
